Ovarian and tubal cancers

Danforth's Obstetrics and Gynecology: Tenth Edition

Volumn , Issue , 2012, Pages 1022-1060

  Cass, Ilana ^a,b   Karlan, Beth Y ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77950104035     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (33)

1. Quirk JT, Natarajan N. Ovarian cancer incidence in the United States, 1992-1999. Gynecol Oncol 2005;97:519-523.
2. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk:collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992;136(10):1184-1203.
3. Smith HO, Berwick M, Verschraegen CF, et al. Incidence and survival rates for female malignant germ cell tumors. Obstet Gynecol 2006;107;1075-1085.
4. Zhang M, Cheung MK, Shin JY, et al. Prognostic factors responsible for survival in sex-cord stromal tumors of the ovary-an analysis of 376 women. Gynecol Oncol 2007;104;396-400.
5. Longacre TA, McKenney JK, Tazelaar HD, et al. Ovarian serous tumors of low malignant potential (borderline tumors):outcome-based study of 276 patients with long-term (=5 year) follow-up. Am J Surg Pathol 2005;29(6):707-723.
6. Seidman JD, Kurman RJ. LMP:ovarian serous borderline tumors:a critical review of the literature with emphasis on prognostic indicators. Human Pathol 2000;31(5):539-557.
7. Zanetta G, Rota S, Chiari S, et al. Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma:a prospective study. J Clin Oncol 2001;19(10):2658-2664.
8. Alvarado-Cabrero I, Young RH, Vamvakas EC, et al. Carcinoma of the fallopian tube:a clinicopathological study of 105 cases with observations on staging and prognostic factors. Gynecol Oncol 1999;72;367-379.
9. Aziz S, Kuperstein G, Rosen B, et al. A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol Oncol 2001;80:341-345.
10. PecorelliS, Odicino F, Maisonneuve P, etal. Carcinoma of the fallopian tube. J Epidemiol Biostat 1998;3(1):63-74.
11. Chu CS, Menzin AW, Leonard DGB, et al. Primary peritoneal carcinoma:a review of the literature. Obstet Gynecol Surv 1999;54(5):323-335.
12. Karlan BY, Baldwin RL, Lopez-Luevanos E, et al. Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer:implications for ovarian cancer screening. Am J Obstet Gynecol 1999;180(4):917-928.
13. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354(1):34-43.
14. Bell J, Brady MF, Young RC, et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma:a Gynecologic Oncology Group study. Gynecol Oncol 2006;102(3):432-439.
15. Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer:a metaanalysis. Gynecol Oncol 2006;103(3):1070-1076.
16. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era:a meta-analysis. J Clin Oncol 2002;20(5):1248- 1259.
17. American Society of Clinical Oncology. American Society of Clinical Oncology policy statement update:genetic testing for cancer susceptibility. J Clin Oncol 2003;21(12):2397-2406.
18. Cass I, Holschneider C, Datta N, et al. BRCA-mutation-associated fallopian tube carcinoma:a distinct clinical phenotype? Obstet Gynecol 2005;106(6):1327-1334.
19. Chen S, Iversen ES, Friebel T, et al. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol 2006;24(6):863-871.
20. Domchek SM, Friebel TM, Neuhausen SL, et al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers:a prospective cohort study. Lancet Oncol 2006;7(3):223- 229.
21. Finch A, Beiner M, Lubinski J, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 2006;296(2):185-192.
22. Guillem JG, Wood WC, Moley JF, et al. ASCO(SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol 2006;24;4642-4660.
23. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302(5645):643-646.
24. NCCN. Genetic(familial high-risk assessment:breast and ovarian cancer. In:Clinical practice guidelines in oncology. 2006.
25. Powell CB, Kenley E, Chen LM, et al. Risk-reducing salpingo- oophorectomy in BRCA mutation carriers:role of serial sectioning in the detection of occult malignancy. J Clin Oncol 2005;23(1):127- 132.
26. Schmeler KM, Lynch HT, Chen LM, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. NEngl J Med 2006;354(3):261-269.Mironov S, Akin O, Pandit-Tasker N, et al. Ovarian cancer. Radiol Clin North Am 2007;45:149-166.
27. Risum S, Hogdall, Loft A, et al. The diagnostic value of PET/CT for primary ovarian cancer-a prospective study. Gynecol Oncol 2007;105:145-149.
28. Ueland FR, DePriest PD, Pavlik EJ, et al. Preoperative differentiation of malignant from benign ovarian tumors:the efficacy of morphology indexing and Doppler flow sonography. Gynecol Oncol 2003;91:46-50.
29. Bast RC Jr, Badgwell D, Lu Z, et al. New tumor markers:CA-125 and beyond. IntJ Gynecol Cancer2005;15(Suppl 3):274-281.
30. Menon U, Skates SJ, Lewis S, et al. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol 2005;23:7919-7926.
31. ACOG Committee Opinion. The role of the generalist obstetrician- gynecologist in the early detection of ovarian cancer. Obstet Gynecol 2002;100:1413-1416.
32. Gostout BS, Brewer MA. Guidelines for referral of the patient with an adnexal mass. Clin Obstet Gynecol 2006;49:448-458.
33. Im SS, Gordon AN, Buttin BM, et al. Validation of referral guidelines for women with pelvic masses. Obstet Gynecol 2005;105:35-41.